cas 24666-56-6|| where to buy 3-Aminopiperidine-2,6-dione Hydrochloride

Product Name:3-Aminopiperidine-2,6-dione Hydrochloride

IUPAC Name:3-aminopiperidine-2,6-dione hydrochloride

Packing Unit	Available Stock	Price($)
CM119077-100g	in stock	ȅȤ
CM119077-500g	in stock	ŸŸƚ
CM119077-1000g	in stock	ƴƴƴ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:24666-56-6; Molecular Formula:C5H9ClN2O2; Melting Point:-; Smiles Code:O=C(C(N)CC1)NC1=O.[H]Cl; Density:

: Catalog Number:CM119077; Molecular Weight:164.59; Boiling Point:; MDL No:MFCD11042437; Storage:Keep in inert atmosphere, store at room temperature.

: Piperidines; Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.; Piperidine,Piperidine Price; if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.

: NX-2127; Existing BTK inhibitors directly bind to the active site of BTK and face challenges such as acquired resistance or incomplete responses over time. PROTAC-induced BTK degradation works as a novel alternative therapy for drug-resistant cancers. The latest journal Science publishes the identification of BTK mutations that are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Nurix Therapeutics’ TPD compound NX-2127 is a first-in-class, dual-function small-molecule protein degrader. It drives targeted BTK and transcription factor IKAROS (IKZF1/3) degradation through ubiquitination and proteasomal degradation, adding combined benefit. NX-2127 is under development of phase I clinical trials that shows promising results and a manageable safety profile for the treatment of relapsed/ refractory B-cell malignancies.